Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

NCT01808950 is registered in ClinicalTrials.gov with Spirig Pharma Ltd. as lead sponsor.

NCT NCT01808950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01808950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)
Lead sponsor
Spirig Pharma Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2013
Completion date
August 31, 2013
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nodular basal cell carcinoma